Is ALTERITY THERAPEUTICS LTD (ATHE) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 62.7% / 30% | 6.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.2% / 33% | 62.7% / 33% | 6.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.3% / 33% | 88.3% / 33% | 8.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 62.7% / 33% | 6.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.3% / 33% | 88.3% / 33% | 8.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 97.5% | |
| Operating Margin | -372.6% | |
| Net Margin | -219.9% | |
| Return on Equity (ROE) | -47.0% | |
| Return on Assets (ROA) | -32.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Total Debt | $155,457 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 22.0 |
| Total Assets | $46M |
Price & Trading
| Last Close | $3.16 |
| 50-Day MA | $3.40 |
| 200-Day MA | $4.05 |
| Avg Volume | 13K |
| Beta | 0.1 |
|
52-Week Range
$2.52
| |
About ALTERITY THERAPEUTICS LTD (ATHE)
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ALTERITY THERAPEUTICS LTD (ATHE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ALTERITY THERAPEUTICS LTD is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ALTERITY THERAPEUTICS LTD's debt ratio?
ALTERITY THERAPEUTICS LTD's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.3%.
What are ALTERITY THERAPEUTICS LTD's key financial metrics?
ALTERITY THERAPEUTICS LTD has a market capitalization of $60M. The company maintains a gross margin of 97.5% and a net margin of -219.9%. Return on equity stands at -47.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.